Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Pediatr Blood Cancer. 2013;60 Suppl 1(Suppl 1):S19-22. doi: 10.1002/pbc.24341. Epub 2012 Oct 25.
Immune thrombocytopenia (ITP) is a syndrome characterized by low platelet counts and an increased risk of bleeding. For most children, ITP is a self-limiting disease; however, for some children and most adults, thrombocytopenia can become chronic. Newer therapies for ITP include rituximab and thrombopoietin (TPO) receptor agonists. Rituximab is a useful second-line therapy and may be splenectomy-sparing. Thrombopoeitin receptor agonists have demonstrated large treatment effects with respect to increasing platelet levels; however, they require maintenance dosing. This review summarizes how these new agents might be positioned in the management of patients with chronic ITP.
免疫性血小板减少症（ITP）是一种以血小板计数降低和出血风险增加为特征的综合征。对于大多数儿童来说，ITP 是一种自限性疾病；然而，对于一些儿童和大多数成年人来说，血小板减少症可能会变成慢性的。ITP 的新疗法包括利妥昔单抗和血小板生成素（TPO）受体激动剂。利妥昔单抗是一种有用的二线治疗方法，可能避免脾切除术。血小板生成素受体激动剂在增加血小板水平方面显示出了很大的治疗效果；然而，它们需要维持剂量。这篇综述总结了这些新药物在慢性 ITP 患者管理中的可能定位。
